Stakeholder cooperation to overcome challenges in orphan medicine development: The example of Duchenne muscular dystrophy

Eugenio Maria Mercuri, Volker Straub, Pavel Balabanov, Kate Bushby, Monica Ensini, Nathalie Goemans, Annamaria De Luca, Alejandra Pereda, Robert Hemmings, Giles Campion, Edward Kaye, Virginia Arechavala-Gomeza, Aurelie Goyenvalle, Erik Niks, Olav Veldhuizen, Pat Furlong, Violeta Stoyanova-Beninska, Matthew J Wood, Alex Johnson, Francesco MuntoniBruno Sepodes, Manuel Haas, Elizabeth Vroom, Annemieke Aartsma-Rus

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Duchenne muscular dystrophy is a rare, progressive, muscle-wasting disease leading to severe disability and premature death. Treatment is currently symptomatic, but several experimental therapies are in development. Implemented care standards, validated outcome measures correlating with clinical benefit, and comprehensive information about the natural history of the disease are essential for regulatory approval of any treatment. However, for Duchenne muscular dystrophy and other rare diseases, these requirements are not always in place when potential therapies enter the clinical trial phase. A cooperative effort of stakeholders in Duchenne muscular dystrophy-including representatives from patients' groups, academia, industry, and regulatory agencies-is aimed at addressing this shortfall by identifying strategies to overcome challenges, developing the tools needed, and collecting relevant data. An open and constructive dialogue among European stakeholders has positively affected development of treatments for Duchenne muscular dystrophy; this approach could serve as a paradigm for development of treatments for rare diseases in general.
Original languageEnglish
Pages (from-to)882-890
Number of pages9
JournalLANCET NEUROLOGY
Volume15
DOIs
Publication statusPublished - 2016

Keywords

  • Neurology (clinical)

Fingerprint

Dive into the research topics of 'Stakeholder cooperation to overcome challenges in orphan medicine development: The example of Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this